Ownership and insider activity for Indaptus Therapeutics, Inc. (INDP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials.
Price
| Price | $3.21 |
| Market Cap | $364M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-04-08 | Lu Qinglai | |||
| 2026-03-23 | Yao Yun | |||
| 2026-03-23 | SINO LION VENTURES Ltd | |||
| 2026-03-23 | Dai Junyi | |||
| 2026-03-23 | Lazar David E. | S-Sale | 196,800 | |
| 2026-03-23 | Lazar David E. | S-Sale | 700,000 | |
| 2026-02-26 | Jabbour Jerome D | A-Award | 25,000 | $52K |
| 2026-02-26 | Jabbour Jerome D | |||
| 2026-02-26 | McMurdo Matthew Charles | |||
| 2026-02-11 | Meckler Jeffrey A | A-Award | 12,136 | $21K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.4M | $53.4M | $39.2M | $9.3M | $1.6M | $39.1M | $9.6M | $13.4M | $5.8M | $8.5M |
| Short-term Investments | $1.9M | $1.8M | $1.3M | $770000 | 0 | 0 | $16.8M | 0 | 0 | 0 |
| Receivables | $721000 | $478000 | $2.0M | $3.5M | 0 | $21056 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $20.7M | $56.3M | $43.6M | $13.7M | $1.7M | $40.4M | $27.2M | $14.0M | $6.6M | $9.3M |
| Property, Plant & Equipment | $4.0M | $8.2M | $12.2M | $3.8M | $1349 | $172888 | $81313 | $173941 | $82175 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $24.7M | $64.5M | $61.5M | $21.3M | $1.8M | $40.6M | $28.1M | $14.9M | $7.3M | $9.3M |
| Accounts Payable | $1.2M | $1.9M | $2.8M | $3.5M | $155957 | $2.6M | $1.4M | $806004 | $870229 | $544057 |
| Short-term Debt | 0 | 0 | 0 | $544000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.9M | $5.7M | $7.7M | $8.3M | $2.0M | $4.6M | $3.4M | $2.8M | $3.4M | $6.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.0M | $5.7M | $8.0M | $9.7M | $2.0M | $4.7M | $3.4M | $2.8M | $3.4M | $6.2M |
| Retained Earnings | -$62.6M | -$98.3M | -$141.8M | -$189.4M | -$8.0M | -$15.7M | -$30.0M | -$45.4M | -$60.4M | -$81.3M |
| Total Equity | $22.7M | $58.8M | $53.5M | $11.5M | -$237701 | $35.9M | $24.6M | $12.1M | $3.9M | $3.2M |
| Total Debt | 0 | 0 | 0 | $1.3M | 0 | $169327 | $80494 | $175053 | $84164 | 0 |
| Net Debt | -$18.3M | -$55.2M | -$40.6M | -$8.7M | -$1.6M | -$39.0M | -$26.4M | -$13.2M | -$5.7M | -$8.5M |
| Working Capital | $18.8M | $50.6M | $35.9M | $5.4M | -$283495 | $35.8M | $23.8M | $11.2M | $3.2M | $3.2M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 19.48 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -18.57 |
Profitability
| Return on Equity | -302.75% |
| Return on Invested Capital | -129.90% |
| Return on Assets | -128.66% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATXI · AZTR · GTBP · LIPO · NKGN · PBM · PTIX
Explore sector: Healthcare · Biotechnology
More sections of INDP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks